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Abstract
Introduction: Triple Negative Breast Carcinomas (TNBC) are more prevalent in younger women especially those
with African Ancestry, in whom the disease appears to be more aggressive. Since there are no data on Africans
living in continental Europe, we sought to analyse a sample of African women from a European country and
determine if, like African Americans, they have more aggressive tumor biology and poorer outcomes.
Methods: We performed a retrospective review of TNBC to compare clinical and pathological features and
survival between African and non-African patients. All women presented with breast cancer (BC), between 2005 and
2014, to a single general hospital, in Portugal.
Results: A total of 144 (9.3% of the whole sample) TNBC patients were identified and amongst these, 17 were
African (12%). African patients were not significantly younger than non-African patients (median age of 60 years vs
57.2 years, respectively, p=0.59). Regarding tumor size, nodal status and histologic grade at presentation, these
variables were very similar between the two cohorts. Nevertheless, the prevalence of initially metastatic BC was
significantly higher among the African population (41.2% vs 11%, p<0,005) and the outcome was worse for these
patients (median survival: 62 vs 15 months, p<0.005).
Conclusions: Our study demonstrated that African patients more frequently presented with late stage disease
and worse survival outcome than the non-African population. These findings may be explained by more aggressive
tumor biology.
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Introduction
Human BC represents a heterogeneous group of tumors. According
to gene expression studies, there are four common molecular
subgroups of BC that vary importantly with respect to clinical features,
natural history and outcomes [1]. In particular, the TNBC (absence of
estrogen receptor (ER), progesterone receptor (PR), and Epithelial
Growth Factor Receptor 2 (HER 2) overexpression) which are
associated with an overall worse prognosis compared to other breast
cancer subtypes. These tumors are more likely to be poorly
differentiated, of higher histological grade, associated with a higher
recurrence rate and, unlike other subtypes, there are no target
therapies. They account for 15-20% of all breast cancer cases, affect
mainly younger women and are more prevalent in those with African
Ancestry [2]. In Senegal and Nigeria TNBC account for 30% [3] and in
Ghana for 82% [4] of all BC cases.
African women with BC have lower survival than British non-
African female patients and their carcinomas are more likely to be
triple negative (TN) and grade 3 [5]. Despite their aggressiveness and
high prevalence in the female population of African ancestry, there is
no data on those living in continental Europe, regarding the incidence
and outcome of patients with TNBC.
Portugal has a high number of African inhabitants originated from
Portuguese-speaking African countries. Since we have observed very
aggressive TNBC in African patients and because data from other
countries with African patients, especially African American, have
confirmed these findings, we decided to determine if African patients
living in a European country would have more aggressive disease and
worse outcome.
To this end, we compared the clinical and pathological
characteristics and the survival of TNBC in African women versus
non-African women, using a consecutive sample of TNBC with a long-
term follow-up from a general hospital. Our institution provides
support to a very heterogeneous population in terms of socioeconomic
status and race/ethnicity, serving the most densely populated area in
the country, and the largest African community living in Portugal.
Materials and Methods
We selected women, of all ages and races/ethnicities, with TNBC
from a consecutive sample of BC patients treated in a single institution
from 2005 until 2014. Details of age at diagnosis; race/ethnicity; tumor
stage, histology and grade; location of tumor metastases; unilateral or
bilateral synchronous/metachronous disease; and estrogen receptor
(ER), progesterone receptor (PR), and Epithelial Growth Factor
Receptor 2 (HER 2) status were recorded. All data were collected from
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hospital’s electronic medical records, patient charts and pathology
reports. Where ethnicity was undisclosed or histological, or
immunohistochemistry, diagnosis was unconfirmed, patients were
excluded. Molecular subtypes other than TNBC were also excluded.
Overall Survival (OS) was calculated based on the day of death or
the date of last follow-up. Statistical analysis was descriptive and
analysis was performed with the use of SPSS Statistics 22nd edition.
Categorical variables are presented as frequencies and percentages, and
continuous variables as means and standard deviations, or medians
and interquartile ranges for variables with skewed distributions.
Survival analysis was performed by the Kaplan Meyer method, with
Log Rank test used to compare survival between groups. All reported
p-values are two-tailed, with a P value of 0.05 indicating statistical
significance.
Results
A total of 1552 patients with BC were identified. Of these, 144 had
TNBC which represented 9.3% of the whole sample.
Of the 144 patients with TNBC, seventeen were African women
(12%). The mean age at the time of the diagnosis for the TNBC
population was 57.5 years. The mean age for the African patients was
60 years compared with 57.2 years for the non-African patients (– t
(18) =-0.54, p=0.59).
The tumor features in the two patient cohorts were compared (Table
1).
Tumor features Non-African no (%) African no (%)
Tumor size
T1 43 (33.9%) 6 (35.2%)
T2 50 (39.4%) 10 (58.8%)
T3 17 (13.4%) 1 (5.9%)




N+ 37 (29.1%) 1 (5.9%)
N0 76 (59.8%) 8 (47.1%)
Unknown 14 (11%) 8 (47.1%)
Total 127 17
Histological grade
1 6 (4.7%) 1 (5.9%)
2 45 (35%) 2 (12.8%)
3 61 (48%) 8 (47%)
Unknown 15 (11.8%) 6 (35%)
Total 127 17
Initial metastatic disease 14 (11%) 7 (41.2%)
Bilateral disease 5 (3,9%) 2 (11.8%)
Adjuvant chemotherapy
Yes 77 (60.6%) 6 (35.3%)
No 37 (29.1%) 10 (58.8%)
Unknown 13 (10.2%) 1 (5.9%)
Total 127 17
Table 1: Clinicopathological tumor features in African and non-African triple negative breast cancer patients.
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Regarding tumor size, 94.1% of the African patients presented with
primary breast tumor size ≤ 5 cm compared with 73.3% of the non-
African patients and 5.9% of the Africans presented with tumor size >5
cm compared with 19.7% of the non-Africans, but we could not find
statistical difference (Fisher’s exact test, p=1).
Nodal involvement was present in one African patient (5.9%) but
was unknown for eight patients. Five of them were initially metastatic,
and three others were over 80 years old, with T1 and T2 tumors, and
were treated with simple mastectomy without lymphadenectomy or
sentinel lymph node assessment.
In the non-African group, 37 patients (29.1%) had nodal
involvement and fourteen patients (11%) had no data available. These
were initially metastatic patients, where surgery was not performed, or
older patients treated with simple mastectomy without axillary staging.
Seven patients were found to have bilateral disease which accounted
for 4.9% of the whole sample. Regarding the histological characteristics
of both lesions, 4 patients had TNBC in both breasts.
Of these, 2 were African patients who presented with synchronous
tumors, and 2 were non-African and presented with metachronous
lesions (time interval to contralateral cancer was 4 and 9 years). The
histological grade assessment showed that 54% of the TNBC
population with available data had grade 3 tumors (47% African; 48%
Non-African).
The missing information in African patients pertained to those who
had initially metastatic disease. In the African group, nine patients
(53%) had metastatic disease. Seven of them, which represented 41.2%
of the African cohort, presented with synchronous disease – one in the
brain, five in the lungs and one in the skin.
And two others developed metachronous metastasis – one in the
bone and the other one in the lungs. Concerning the non-African
patients, there were thirty-eight metastasized patients (30%), fourteen
of them (11%) ab initio – four with lung metastases, three with lymph
node metastasis, two with liver metastasis, two with brain metastasis,
two with bone metastasis and one with peritoneal metastasis.
The other twenty-four developed metastasis during the course of the
disease – eleven with lymph node metastasis, four in the lungs, three in
the bone, three in the liver and three in the skin.
The percentage of initially metastatic BC was significantly higher
among the TNBC African population (Two-sided Fisher’s exact test
p<0.005). Analyzing survival, 102 of the 144 patients (70.8%) are alive,
seven of them are African (41.2% of the African group). Of the 42
patients who died, 6 of them died of non-BC related causes.
Excluding these patients, the median survival for the TNBC
population was 62 months. Considering the groups, the median
survival was 62 months for the non-Africans compared with 15
months for the Africans (Log Rank= 8.72, p< 0.005) (Figure 1).
Concerning the African TNBC population, ten patients have died.
Two of them died of non-breast cancer related causes and eight
patients died of metastatic breast cancer. Of these 8 patients, six were
initially metastatic and two became so during follow-up (one had a
survival of 3 months and the other one of 1 month after the diagnosis
of metastatic disease). There is one patient, who had initially metastatic
BC, that is still alive with a survival of 9 months.
Figure 1: Kaplan Meier overall survival curve for African patients vs
non-African patients with triple negative breast cancer (Log Rank=
8.72, p<0.005)
Discussion
In the Carolina Breast Cancer Study, the percentage of patients with
TNBC was 20% [6], in our dataset it was only 9.3%. Despite other
series showing early age of onset of TNBC or early age of onset of
breast cancer in Africans, in our analysis we were not able to show this
difference. Stead LA et al. [7] have documented increased, equivalent
proportions of TNBC both in younger and older African women.
In our series of patients, we were able to show that Africans with
TNBC had higher prevalence of initially metastatic breast cancer when
compared to non-African patients with TNBC. This finding has not
before been reported in the literature. Regarding bilateral disease, we
found that four of our patients with bilateral BC had TN tumors. Two
of them were African with synchronous tumors at the time of
diagnosis which may, in part, reflect the aggressiveness of the disease
in this population.
Other series of TNBC and of BC in African patients showed that BC
in Africans are more frequently poorly differentiated [8]. In our dataset
we did not draw this conclusion. We have found, in the whole sample,
a high prevalence of poorly differentiated carcinomas, which was
around 50%.
We were not able to find differences with regard to tumor size and
nodal involvement, at the time of diagnosis, between the African and
non-African populations. Nevertheless, it is interesting to notice that
despite this similarity more African patients presented with metastatic
disease and had worse survival outcome. This, in line with other
previous reports, shows that the worse prognosis in Africans may not
only be due to late diagnosis but to an underlying aggressive biology
[9]. The Southwest Oncology Group reported similar clinical trial data.
In a retrospective analysis of a large clinical trial database, authors [10]
were able to show that in stage-matched and treatment-matched
patients, with adjustment to socioeconomic status, there is worse
prognosis in early African American BC patients when compared to
white patients.
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The main limitations of our study were the very small numbers,
namely only seventeen patients were African. This fact probably did
not allow us to show statistical significance in certain comparisons,
and hence draw some conclusions. The other limitation was the
retrospective nature of this study, and probably more African patients
could have been identified. The socioeconomic status was another
limitation, which in this series may have been a confounding factor. In
the population served by our institution, the Africans have a lower
socioeconomic status which may concur to late diagnosis and non-
compliance with therapy enhancing the effect of race and decreased
survival in TNBC.
It is important, therefore, to target this population to raise their
awareness to the risk factors of breast cancer, the importance of self-
examination and the early presentation with clinical signs. The access
to the health care services should be made easier and alterations to the
screening services offered to the black populations might be
considered.
We may conclude that given their worse prognosis, African patients
with TNBC may be considered upfront for referral to Palliative care.
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